Cecilia Choi, MD
Hematology & Oncology · Makawao, HINPI 1558562371
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,943 of the $4,415 with a category attached, or 66.7%. 32 manufacturers reported payments, led by Novartis at 30.7% of the total. 2025 is the largest year on record at $3,023, more than ten times the $24 reported in 2020.
Across 123 payments — averaging $35.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- AstraZeneca$449
- E.r. Squibb & Sons, L.L.C.$422
- Pfizer$297
- Caris MPI, Inc.$228
- Astellas Pharma US Inc$221
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,94367%
- Education$3758%
- Other$1,09725%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 24 | $1,354 |
| AstraZeneca(2 entities) | 15 | $449 |
| E.r. Squibb & Sons, L.L.C. | 17 | $422 |
| Pfizer | 8 | $297 |
| Caris MPI, Inc. | 3 | $228 |
| Astellas Pharma US Inc | 5 | $221 |
| Johnson & Johnson | 5 | $131 |
| Eisai Inc. | 6 | $128 |
| AVEO Pharmaceuticals, Inc. | 2 | $119 |
| Beone Medicines USA, Inc. | 1 | $103 |
| Seagen Inc. | 1 | $99 |
| Tempus AI, Inc | 4 | $92 |
| Regeneron Healthcare Solutions, Inc. | 3 | $86 |
| Array Biopharma Inc | 3 | $82 |
| Boehringer Ingelheim | 2 | $57 |
| Bayer | 2 | $54 |
| Gilead | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Genentech USA, Inc. | 2 | $44 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| EMD Serono, Inc. | 2 | $41 |
| Merck | 1 | $31 |
| Deciphera Pharmaceuticals Inc. | 1 | $29 |
| AbbVie | 1 | $26 |
| Foundation Medicine, Inc. | 1 | $24 |
| Blueprint Medicines Corporation | 1 | $23 |
| Novocure Inc. | 1 | $23 |
| Taiho Oncology, Inc. | 1 | $22 |
| Stemline Therapeutics Inc. | 1 | $22 |
| Urogen Pharma, Inc. | 1 | $22 |
| Springworks Therapeutics, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$150
- MI CANCER SEEK$127
- XTANDI$125
- IMFINZI$120
- TEVIMBRA$103
How this compares
$4,415 in reported general payments places this provider in the 70th percentile of 42 hematology & oncology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KeytrudaPembrolizumab | 78 | $997,233 |
| XtandiEnzalutamide | 20 | $226,162 |
| OpdivoNivolumab | 18 | $187,792 |
| IbrancePalbociclib | 11 | $172,990 |
| XgevaDenosumab | 51 | $163,339 |
| OrgovyxRelugolix | 54 | $142,857 |
| LonsurfTrifluridine/Tipiracil Hcl | 14 | $126,619 |
| ReblozylLuspatercept-Aamt | 12 | $112,301 |
| ProliaDenosumab | 34 | $58,973 |
| CreonLipase/Protease/Amylase | 31 | $11,488 |
| XareltoRivaroxaban | 11 | $7,759 |
| EliquisApixaban | 11 | $6,389 |
| Anastrozole | 70 | $3,144 |
| Letrozole | 109 | $2,135 |
| Fentanyl | 11 | $1,482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckKeytruda | $31 | $997,23378 claims |
| E.r. Squibb & Sons, L.L.C.Opdivo, Reblozyl | $422 | $300,09330 claims |
| Astellas Pharma US IncXtandi | $221 | $226,16220 claims |
| PfizerIbrance, Eliquis | $297 | $179,37922 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $43 | $142,85754 claims |
| Taiho Oncology, Inc.Lonsurf | $22 | $126,61914 claims |
| AbbVieCreon | $26 | $11,48831 claims |
| Johnson & JohnsonXarelto | $131 | $7,75911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 42 hematology & oncology providers in Hawaii.
Other hematology & oncology in Makawao
- Tamie KernsHonolulu$48K
- David TamuraHonolulu$31K
- Melvin PalalayHonolulu$20K
- Ryon NakasoneHonolulu$20K
- Arnold YeeHonolulu$17K
- Jared AcobaHonolulu$15K
- Swaty AroraHonolulu$15K
- Ramin AltahaWailuku$13K
- William LouiHonolulu$12K
- Jodi KagiharaHonolulu$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.